Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects.
The author has tried to extrapolate on several neurological diseases of the ageing, Knoll's proposition to treat Parkinson's disease chronically for relapse prevention, by MAO-B. At this occasion, the author makes a critical review of the clinical trial results concerning the new different series of depression treatments, as most authors propose today to use some new ones not only in depression, but in Parkinson's and Alzheimer's diseases and in ageing.
Mathé
G
G
D000375:Aging / Q000187:drug effects; D000544:Alzheimer Disease / Q000188:drug therapy; D003131:Combined Modality Therapy; D003863:Depression / Q000188:drug therapy*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy
D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents